These foregoing results together point towards a general tumor-suppressor role of MIR211. By contrast, MIR211 is also known exhibit high expression levels in certain melanoma subtypes and in other cancers: MIR211 expression is high in a majority (6/8) of melanoma lines in the NCI-60 cancer cell panel (76), and in 9/29 clinical melanoma samples (12), suggesting that either MIR211 level by itself is irrelevant to the tumor-like status or malignancy or that in certain cancer cells MIR211 levels might have tumor-promoting activity. The gene discussed is MIR211; the disease is cancer.